Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial.
We examined the effects of the long-term ingestion of dietary diacylglycerols (DG) in a double-blind controlled study of human lipid metabolism. Healthy men (n = 38; aged from 27 to 49 y, body mass index (BMI) ranging from 21.8 to 27.4 kg/m(2)) completed the study. To accustom the subjects to the test diets prior to the experiment, they were supplied with test diets of triacylglycerol (TG) oil for 4 wk (control period). The test oils (10 g/d) were included in bread, mayonnaise or shortbread and served for the breakfast. The target for total lipid intake was 50 g/d (15 g for breakfast, 15 g for lunch and 20 g for dinner) throughout the study. The subjects were then divided into two groups so that mean BMI and the hepatic fat content, determined by computed tomography, for each group were not different. One group (DG group) consumed test meals containing DG-rich oil (10 g/d) while the other group (TG group) consumed the same meal as during the control period. Ten grams of the DG-rich oil contained 5.5 g 1,3-DG, 2.5 g 1,2-DG and 2 g TG. The actual lipid intake during the study was 43 g/d. Body weight, BMI and waist circumference decreased in both groups at the end of the test period of 16 wk. However, the magnitudes of decreases in these variables were significantly greater in the DG group than in the TG group. Decreases of total fat, visceral fat area and subcutaneous fat area of the abdominal traverse images of computed tomography in the DG group were also significantly greater than those in the TG group. Hepatic fat content decreased significantly in the DG group while no change was observed in the TG group. Serum lipid concentrations (TG, total cholesterol, free fatty acid) and related metabolites (glucose, insulin, total ketone body) did not change significantly in either group. Thus, in contrast to TG, DG apparently suppressed accumulation of fat and possibly reduces the risk of diseases associated with visceral fat obesity.
Nagao
T
T
Biological Science Laboratories, Kao Corporation, Tochigi, 321-3497, Japan.
Watanabe
H
H
Goto
N
N
Onizawa
K
K
Taguchi
H
H
Matsuo
N
N
Yasukawa
T
T
Tsushima
R
R
Shimasaki
H
H
Itakura
H
H
D000005:Abdomen / Q000033:anatomy & histology; D000273:Adipose Tissue / Q000033:anatomy & histology*; D000328:Adult; D001824:Body Constitution; D004032:Diet; D004075:Diglycerides / Q000008:administration & dosage* / Q000494:pharmacology; D004311:Double-Blind Method; D002149:Energy Intake; D006801:Humans; D008099:Liver / Q000033:anatomy & histology; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000008:administration & dosage* / Q000494:pharmacology
D004075:Diglycerides; D014280:Triglycerides